| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2024 | Developing Standard Criteria and Applications for Identifying Antimalarial Drug Treatments Based on the Blood Stage Morphology of P. falciparum | Wellcome Trust (iTP) | Prof. Kesinee Chotivanich |
| 2 | 2020 | การประยุกต์ใช้เทคนิคการสร้างภาพฟลูออเรสเซนต์จากอนุภาคนาโนในการดูผลของยารักษามาลาเรียต่อเชื้อมาลาเรียในระยะติดต่อในตับ | Mahidol University (Government Budget) | Prof. Kesinee Chotivanich |
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2025 | A Phase 1 clinical trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 followed by CH505 TF mRNA-gp160 in adults in overall good health without HIV | Fred Hutchinson Cancer Center Prime Award :NIH | Prof. Emeritus Punnee Pitisuttithum |
| 2 | 2024 | AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections | National Institutes of Health (NIH) | Prof. Emeritus Punnee Pitisuttithum |
| 3 | 2021 | Randomized, Double Blind Evaluation of Late Boost Strategies with IHV01 (FLSC in aluminum phosphate) and A244 with or without ALFQ for HIV-uninfected Participants in the HIV Vaccine Trial RV306 / WRAIR 1920 (RV546) | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Prof. Emeritus Punnee Pitisuttithum |
| 4 | 2020 | The Military HIV Research Program (MHRP) Clinical Trial Unit | National Institute of Health (NIH) | Prof. Emeritus Punnee Pitisuttithum |
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2025 | การต่อสู้โรคด้วยวัคซีน:NRCT9-3 ประสิทธิผลของวัคซีนป้องกันการติดเชื้อเอชพีวี หลังจากได้รับวัคซีนหนึ่งเข็มหรือสองเข็มในวัยรุ่นและผู้หญิงวัยเจริญพันธุ์ | Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc./Prime Award: NIH | Prof. Emeritus Punnee Pitisuttithum |
| 2 | 2020 | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age (V503-049) | MSD (THAILAND) Company Limited | Prof. Emeritus Punnee Pitisuttithum |
Other Infectious Diseases (Chikungunya, Melioidosis, Rabies, Respiratory Syncytial Virus Infection, Tuberculosis, Diphtheria, Tetanus, Pertussis, Hand, Food and mouth disease, Pneumococcal)
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2024 | การประเมินโอกาสการเสียชีวิตของคนไข้โรคเมลิออยโดซิสจากพันธุกรรมของเชื้อและคนไข้ | Health Systems Research Institute | Dr. Chewapreecha Kamolchanok Claire |
| 2 | 2023 | บทบาทของการรั่วของโมเลกุลของเชื้อโรคจากลำไส้จากการให้แอลกอฮอล์ในหนูที่เป็นโรคลุปัสจากการขาดโมเลกุล FcgRllb | Mahidol University (MU’s Strategic Research Fund) | Assoc. Prof. Wiwat Chancharoenthana |
| 3 | 2023 | Blood microbiome and metabolome in cecal ligation and puncture mice support a better impact of short-chain fatty acid-producing bacteria than other probiotics | Mahidol University (Specific League Funds) | Assoc. Prof. Wiwat Chancharoenthana |
| 4 | 2023 | An update on nationwide surveillance of hospitalized pneumococcal disease burden among Thai adulta 2011-2023: an bidirectional cohort study | Mahidol University (Specific League Funds) | Assoc. Prof. Thundon Ngamprasertchai |
| 5 | 2022 | A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older | Government Pharmaceutical Organization | Prof. Emeritus Punnee Pitisuttithum |
| 6 | 2022 | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults | Sanofi Pasteur Inc. | Asst. Prof. Wasin Matsee |
| 7 | 2021 | A Phase II/III Adaptive Seamless Design, rancomized, controlled Trial To Evaluate And Immunogenicity of 2 Dose-Regimen of BBV87 Chikungunya Vaccine in Healthy Subjects Aged 12 to 65 years in Panama, Colombia, and Thailand | International Vaccine Institute, Korea | Prof. Emeritus Punnee Pitisuttithum |
| 8 | 2021 | Incidence and clinical characteristics of Respiratory syncytial Virus Infection in influenza-like illness among adults in Thailand | Mahidol University (New discovery and Frontier Research) | Assoc. Prof. Chayasin Mansanguan |
| 9 | 2021 | The integration of single cell analysis for immune profiling study inactive tuberculosis and latent tuberculosis infection | Thailand Science Research and Innovation | Assoc. Prof. Wiwat Chancharoenthana |
| 10 | 2021 | A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) Infection who are at High Risk for RSV-related Disease Progression | Janssen-Cilag limited | Asst. Prof. Sant Muangnoicharoen |
| 11 | 2021 | Tracking transmission of Enterovirus causing hand, foot and mouth disease between index cases and their close contacts in kindergarten schools using the viral next-generation sequencing data | Mahidol University (Specific League Funds) | Dr. Janjira Thaipadungpanit |
| 12 | 2021 | Non-sputum based tuberculosis diagnosis and treatment monitoring | Mahidol-Oxford Tropical Medicine Research Unit: MORU | Dr. Janjira Thaipadungpanit |
| 13 | 2020 | Development, production and clinical evaluation on safety and immunogenicity of recombinant pertussis vaccine (recombinant DTaP) for pediatrics | National Science and Technology Development Agency | Prof. Emeritus Punnee Pitisuttithum |
| 14 | 2020 | A randomized, observer-blind, active-controlled study to assess safety and immunogenicity of a licensed tetanus-diphtheria-recombinant acellular pertussis vaccine (TdaP, Boostagen®) and a pediatric diphtheria-tetanus- recombinant aP (recombinant DTaP) vaccine when administered to healthy children aged 3-7 years | BioNet-Asia | Prof. Emeritus Punnee Pitisuttithum |
| 15 | 2020 | A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114 in healthy infants, children | MSD (THAILAND) LTD. | Prof. Emeritus Punnee Pitisuttithum |
| 16 | 2020 | Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum free (VRVg) Assessed with the Institut Pasteur du Cambodge (IPC :2-2-2-0-0) and the Thai Red Cross (TRC : 2-2-2-0-2) Intradermal Regimens as Simulated Rabies Post Exposure Prophylaxis in Healthy Subjects in Thailand (VRV-009) | Sanofi Pasteur Inc. | Prof. Emeritus Punnee Pitisuttithum |
| 17 | 2020 | A phase II/III randomized, observer-blind, active-controlled study to compare non-inferior immunogenicity of a combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine to a licensed DTaP based vaccine (nonrecombinant),when administered to healthy toddlers aged of 15-36 months old (DTA201) | BioNet-Asia | Prof. Emeritus Punnee Pitisuttithum |
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2022 | A Phase 2/3, randomized, double-blind, double-dummy, Placebo-controlled study to evaluate the safety and efficacy of 2 regimens of orally administered PF-07321332/ritonavir in preventing symptomatic sars-cov-2 infection in adult household contacts of individuals with sars-cov-2 infection | PAREXEL International (Thailand) Co. Ltd. | Assoc. Prof. Weerapong Phumratanaprapin |
| 2 | 2021 | A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand (GPO NDV-HXP-S) | Government Pharmaceutical Organization | Prof. Emeritus Punnee Pitisuttithum |
| 3 | 2021 | A Phase 1/2 Study to Evaluate the Safety Reactogenicity and Immunogenicity of Ad26.COV2.S Administered as a Heterologous Booster Vaccination in Adults 18 Years of Age and Older Following Single- or Two-Dose Vaccination with an Inactivated COVID-19 Vaccine | Johnson & Johnson | Prof. Emeritus Punnee Pitisuttithum |
| 4 | 2021 | Development and evaluation of serological assays for COVID-19 by ELISA technique : the implication of the use the Thailand | Mahidol University (New discovery and Frontier Research) | Assoc. Prof. Viravarn Luvira |
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2023 | การศึกษาวิจัยในศูนย์การศึกษาหลายแห่ง ระยะที่ 2 แบบสุ่ม ปกปิดข้อมูลทั้งสองด้าน ควบคุมด้วยยาหลอก มีแนวทางการให้ยาด้วยการจับคู่ยาหลอก (แบบดับเบิลดัมมี) เพื่อประเมินประสิทธิผลและความปลอดภัยของยาเจเอ็นเจ-64281802 สองแบบแผนการให้ยาสำหรับการป้องกันการติดเชื้อไข้เลือดออก | Janssen Research & Development LLC | Asst. Prof. Sant Muangnoicharoen |
| 2 | 2022 | A Phase 2, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate pharmacoki/netics, pharmacodynamics, and safety of AT-752 in patients with dengue infection | Atea Pharmaceutical, Inc | Assoc. Prof. Weerapong Phumratanaprapin |
| 3 | 2021 | Enhancing Diagnostic Value of Dengue NS1 in Plasma by Viral Enrichment Sample Preparation and Exosome Extraction | Mahidol University (Specific League Funds) | Assoc. Prof. Viravarn Luvira |
| 4 | 2020 | Relationship between immune profiling and leaky gut syndrome in dengue infection | Thailand Science Research and Innovation | Assoc. Prof. Wiwat Chancharoenthana |
| 5 | 2020 | DEN/Zika/CHIK infection among febrile patients in Hospital for Tropical Diseases, Bangkok, Thailand | University of Colorado | Asst. Prof. Wasin Matsee |
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2023 | A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Quadrivalent Inactived Split Virion Influenza Vaccine in Healthy Thais | Government Pharmaceutical Organization | Prof. Emeritus Punnee Pitisuttithum |
| 2 | 2021 | A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Above | PAREXEL International (Thailand) Co. Ltd. | Prof. Emeritus Punnee Pitisuttithum |
| 3 | 2020 | A Phase III Double Blinded, Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Subjects Aged 65 Years and above (GPO Tri Fluvac Vaccine Phase III_Elderly) | Government Pharmaceutical Organization | Prof. Emeritus Punnee Pitisuttithum |
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2020 | A Multi-country Varicella Economic Burden Study (MARVEL II) – Thailand | Merck Sharp & Dohme Corp., a Subsidiary of Merk & Co., Inc. | Asst. Prof. Supitcha Kamolratanakul |
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2022 | COVID-19 International Traveler Sentinel Surveillance (CITrSS) | International society of Travel Medicine (ISTM) | Asst. Prof. Wasin Matsee |
| 2 | 2020 | Analysis of the gut microbiome among western travelers in Thailand | Global emerging infectious disease surveillance (GEIS) sustainment fund FY18-19 | Assoc. Prof. Kittiyod Poovorawan |
General Medicine (Gastrointestinal, Chest, Liver, Kidney, Cardiovascular, Diabetes Mellitus, Cancer, Pharmacology)
| No. | Year | Research Title | Grant | Principal Investigator |
| 1 | 2024 | การศึกษาทบทวนเพื่อรวบรวมข้อมูลวัคซีนสำหรับการสนับสนุนการตัดสินใจเชิงนโยบาย | National Vaccine Institute | Prof. Emeritus Punnee Pitisuttithum |
| 2 | 2024 | A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection | Vaccitech (UK) Ltd, | Assoc. Prof. Kittiyod Poovorawan |
| 3 | 2023 | การต่อสู้โรคเขตร้อนด้วยวัคซีน | National Research Council of Thailand | Prof. Emeritus Punnee Pitisuttithum |
| 4 | 2022 | การแยกลักษณะของเซลล์ในสไลด์สเมียร์เลือดด้วยปัญญาประดิษฐ์ระหว่างผู้ป่วยไข้เฉียบพลันและผู้ป่วยโรคมะเร็งโรคเลือด | Mahidol University (Specific League Funds) | Assoc. Prof. Supat Chamnanchanunt |
| 5 | 2022 | Bacterial-free DNA in blood from bilateral nephrectomy mice enhanced uremic inflammation through cGAS and aryk hydrocarbon receptor | Mahidol University (Specific League Funds) | Assoc. Prof. Wiwat Chancharoenthana |
| 6 | 2021 | A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received and Responded to GSK3228836 in a Previous Treatment Study | GlaxoSmithKline Research & Development Limited | Assoc. Prof. Kittiyod Poovorawan |
| 7 | 2021 | A Double-Blind, Randomized Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-836, an HBV Capsid Inhibitor, in Healthy Subjects, with Chronic HBV Infection | Novotech Clinical Research (Thailand) Co., LTD | Assoc. Prof. Kittiyod Poovorawan |
| 8 | 2021 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Novotech Clinical Research (Thailand) Co., LTD | Assoc. Prof. Kittiyod Poovorawan |
| 9 | 2021 | The prototype digital vaccination registry study: turning clinical data into favorable platform | Mahidol-Oxford Tropical Medicine Research Unit: MORU | Assoc. Prof. Thundon Ngamprasertchai |
| 10 | 2020 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU-PLAN) | Merck Sharp & Dohme Corp., a Subsidiary of Merk & Co., Inc. | Prof. Emeritus Punnee Pitisuttithum |
| 11 | 2020 | Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination with Pegylated Interferon Alpha-2a | Vir Biotechnology, USA | Assoc. Prof. Kittiyod Poovorawan |
| 12 | 2020 | Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear) | GlaxoSmithKline Research & Development Limited | Assoc. Prof. Kittiyod Poovorawan |